articleTop 10% cited
Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma
Archives of Ophthalmology · 2005 · Vol. 123(12) · pp. 1639–1639
Marie Diener‐West✉(Zimmer Biomet (United States))Sandra M. ReynoldsDonna J AgugliaroRobert CaldwellKristi CummingJohn D. EarleBarbara S. HawkinsJames A. HaymanIshmael JaiyesimiLee M. Jampol(Ophthalmology Associates (United States))John M. KirkwoodWui‐Jin KohDennis M. RobertsonJohn M. ShawBradley R. StraatsmaJonni Thoma
Abstract
Metastasis rate increased significantly with increasing primary tumor dimensions at time of patient enrollment. Prognosis after metastatic disease remains poor. Effective methods are needed to prevent, diagnose, and treat metastasis from choroidal melanoma.
Ocular Oncology and TreatmentsCutaneous Melanoma Detection and ManagementRetinal Development and DisordersMedicineChoroidal melanomaDiseaseMelanomaClinical trialOncologyOphthalmologyIntensive care medicineInternal medicineCancer research
MeSH terms
AgedBrachytherapyChoroid NeoplasmsFemaleFollow-Up StudiesHumansIodine RadioisotopesMaleMelanomaMiddle AgedNeoplasm MetastasisProspective StudiesTime FactorsSurvival RateRandomized Controlled Trials as Topic
Citations
614
FWCI
5.69
field-weighted impact
References
15
Percentile
96%
vs. same field & year
Citations per year
References
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Investigative Ophthalmology & Visual Science · 2003 · 1,041 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.